Thank you to our speakers, sponsors, and delegates who joined us in Boston!
If you are interested in the 2026 event, please get in touch at info@hansonwade.com
Showcasing Novel Linker & Conjugation Technologies to Optimize Stability & Reduce Hydrophobicity & Aggregation to Better Balance Safety & Efficacy
As dual-payload and novel-payload ADCs fuel the next wave of innovation in the ADC space, the spotlight is shifting to the chemistry behind these advancements. With the need for strategies to overcome payload hydrophobicity, achieve optimal stability profiles, and reduce aggregation, linker and conjugation strategies have become crucial levers for unlocking improved therapeutic windows.
The 3rd ADC Linker & Conjugation Summit was the only meeting fully dedicated to the chemistry that underpins ADC success. In a rapidly evolving R&D landscape and a highly competitive industry, gaining first-hand insights from key stakeholders through networking sessions and poster presentations is essential to stay ahead of the curve. There were 80+ experts from AstraZeneca, Pfizer, Sutro Biopharma, Glykos, Catena Biosciences, Tubulis, and more for three days of focused insights and technical exchange.
Attendees uncovered innovations in linker design and conjugation chemistry, explored how to conjugate multiple payloads with precision, and discovered how structural modifications translate to clinical impact.
The 4th ADC Linker & Conjugation Summit will return in June 2026 to focus on the key element of the ADC that drives its performance: the linker and conjugation strategy.
The ADC field is a fast moving and complex discipline that requires the coordinated activity of the antibody, its sites of conjugation, and the chemistry of the linkers and payloads to effectively deliver to and kill cancer cells. I look forward to learning about the advances in each of these areas and how they are being combined to address current challenges with ADCs.
Marcello Morelli, Principal Scientist, AstraZeneca
Excited to hear about the new developments in the linker and conjugation fields as well as connect with the experts of this area to tackle the challenges together!
Lea Rochet, Conjugation Scientist, ADC Therapeutics
Explore the Full 2025 Event Guide
- 18+ World Class Speakers
- 3 Days of Dedicated Linker & Conjugation Content
- Exclusive Networking & Partnering Opportunities
2025 Speaker Faculty Included:
2025 Official Partners
2025's Attending Companies Include
Explore the 2025 Agenda
Hear the latest industry-led breakthroughs and gain exclusive insights on linker and conjugation strategies during our packed agenda, discussion sessions and structured networking.
Partner With Us
Join leading ADC developers exploring ways to improve the therapeutic window through optimized linker and conjugation chemistry. Connect with top platform providers, CDMOs, and CROs to position your brand at the forefront of a competitive market.
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.